Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications

Implications and management for clinical practice

R. Douglas Bruce, Frederick L. Altice, Marc Gourevitch, Gerald H. Friedland

Research output: Contribution to journalReview article

Abstract

Background: Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide. Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur. Methods: We reviewed English, Spanish, French, and Italian language articles from 1966 to 2005 in Medline using the following keywords: HIV, AIDS, HIV therapy, antiretroviral therapy, HAART, drug interactions, methadone, and buprenorphine. Additionally, we reviewed abstracts from national and international meetings and conference proceedings. Selected references from these articles were reviewed as well. Results: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone and most approved antiretroviral therapies. Important pharmacokinetic drug interactions have been demonstrated within each class of agents, affecting either methadone or antiretroviral agents. Few studies, however, have been conducted with buprenorphine. The metabolism of both therapies, description of the known interactions, and clinical implications and management of these interactions are reviewed. Conclusions: Certain interactions between methadone and antiretroviral medications are known and may have important clinical consequences. To optimize care, clinicians must be alert to these interactions and have a basic knowledge regarding their management.

Original languageEnglish (US)
Pages (from-to)563-572
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume41
Issue number5
DOIs
StatePublished - Apr 2006

Fingerprint

Practice Management
Drug Interactions
Opioid Analgesics
Pharmacokinetics
Methadone
Buprenorphine
HIV
Acquired Immunodeficiency Syndrome
Therapeutics
Anti-Retroviral Agents
HIV-2
Highly Active Antiretroviral Therapy
Language

Keywords

  • Antiretroviral therapy
  • Buprenorphine
  • Drug interactions
  • HIV/AIDS
  • Methadone
  • Pharmacokinetics

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications : Implications and management for clinical practice. / Bruce, R. Douglas; Altice, Frederick L.; Gourevitch, Marc; Friedland, Gerald H.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 41, No. 5, 04.2006, p. 563-572.

Research output: Contribution to journalReview article

@article{78d17785de5a4b2d9726e613e2f0f69e,
title = "Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice",
abstract = "Background: Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide. Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur. Methods: We reviewed English, Spanish, French, and Italian language articles from 1966 to 2005 in Medline using the following keywords: HIV, AIDS, HIV therapy, antiretroviral therapy, HAART, drug interactions, methadone, and buprenorphine. Additionally, we reviewed abstracts from national and international meetings and conference proceedings. Selected references from these articles were reviewed as well. Results: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone and most approved antiretroviral therapies. Important pharmacokinetic drug interactions have been demonstrated within each class of agents, affecting either methadone or antiretroviral agents. Few studies, however, have been conducted with buprenorphine. The metabolism of both therapies, description of the known interactions, and clinical implications and management of these interactions are reviewed. Conclusions: Certain interactions between methadone and antiretroviral medications are known and may have important clinical consequences. To optimize care, clinicians must be alert to these interactions and have a basic knowledge regarding their management.",
keywords = "Antiretroviral therapy, Buprenorphine, Drug interactions, HIV/AIDS, Methadone, Pharmacokinetics",
author = "Bruce, {R. Douglas} and Altice, {Frederick L.} and Marc Gourevitch and Friedland, {Gerald H.}",
year = "2006",
month = "4",
doi = "10.1097/01.qai.0000219769.89679.ec",
language = "English (US)",
volume = "41",
pages = "563--572",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications

T2 - Implications and management for clinical practice

AU - Bruce, R. Douglas

AU - Altice, Frederick L.

AU - Gourevitch, Marc

AU - Friedland, Gerald H.

PY - 2006/4

Y1 - 2006/4

N2 - Background: Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide. Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur. Methods: We reviewed English, Spanish, French, and Italian language articles from 1966 to 2005 in Medline using the following keywords: HIV, AIDS, HIV therapy, antiretroviral therapy, HAART, drug interactions, methadone, and buprenorphine. Additionally, we reviewed abstracts from national and international meetings and conference proceedings. Selected references from these articles were reviewed as well. Results: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone and most approved antiretroviral therapies. Important pharmacokinetic drug interactions have been demonstrated within each class of agents, affecting either methadone or antiretroviral agents. Few studies, however, have been conducted with buprenorphine. The metabolism of both therapies, description of the known interactions, and clinical implications and management of these interactions are reviewed. Conclusions: Certain interactions between methadone and antiretroviral medications are known and may have important clinical consequences. To optimize care, clinicians must be alert to these interactions and have a basic knowledge regarding their management.

AB - Background: Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide. Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur. Methods: We reviewed English, Spanish, French, and Italian language articles from 1966 to 2005 in Medline using the following keywords: HIV, AIDS, HIV therapy, antiretroviral therapy, HAART, drug interactions, methadone, and buprenorphine. Additionally, we reviewed abstracts from national and international meetings and conference proceedings. Selected references from these articles were reviewed as well. Results: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone and most approved antiretroviral therapies. Important pharmacokinetic drug interactions have been demonstrated within each class of agents, affecting either methadone or antiretroviral agents. Few studies, however, have been conducted with buprenorphine. The metabolism of both therapies, description of the known interactions, and clinical implications and management of these interactions are reviewed. Conclusions: Certain interactions between methadone and antiretroviral medications are known and may have important clinical consequences. To optimize care, clinicians must be alert to these interactions and have a basic knowledge regarding their management.

KW - Antiretroviral therapy

KW - Buprenorphine

KW - Drug interactions

KW - HIV/AIDS

KW - Methadone

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=33646776797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646776797&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000219769.89679.ec

DO - 10.1097/01.qai.0000219769.89679.ec

M3 - Review article

VL - 41

SP - 563

EP - 572

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -